We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...

With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell resistance to current immunotherapies, has signed a collaboration and ...

Shares of AbbVie Inc. ABBV slipped 0.95% to $187.85 Friday, on what proved to be an all-around dismal trading session for the ...

Roopal Thakkar; Executive Vice President, Research & Development and Chief Scientific Officer; AbbVie Inc Scott Reents; Chief Financial Officer, Executive Vice President; AbbVie Inc Good morning ...

Dividend Increase: 5.8% to $1.64 per share, starting in 2025. AbbVie Inc (NYSE:ABBV) reported sales that were $260 million above expectations, driven by robust mid-single-digit operational sales ...

(RTTNews) - While reporting financial results for the third quarter on Wednesday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2024.

Abbvie ( (ABBV) ) has realeased its Q3 earnings. Here is a breakdown of the information Abbvie presented to its investors. AbbVie Inc. is a ...

NORTH CHICAGO, Ill. — NORTH CHICAGO, Ill. — AbbVie Inc. (ABBV) on Wednesday reported third-quarter profit of $1.56 billion. On a per-share basis, the North Chicago, Illinois-based company said it had ...